Stock Library / SYRE

SYRE Healthcare Latest YouTube: Q2 2026 Published 2026-08-10

Spyre Therapeutics, Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Spyre Therapeutics (SYRE) Q2 2026 Earnings: The 40-Cent Beat That Belongs To Somebody Else

Published 2026-08-10

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-10

Podcast available

Yes

Current price

$103.13

+0.77 (+0.75%)

Trailing / Forward P/E

—

Forward: -29.95x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

—

Earnings: —

Margins

0.0% op

Gross: 0.0% · Net: 0.0%

Balance sheet

18.53x current

Debt / Equity: —

52-week range / Beta

$14.51 - $108.14

Beta: 3.03

Analyst target

$124.71

Upside: 20.9%

Cash / shareholder return

-0.98% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: 9.51x

Return on equity: -23.0%

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Price chart

Market context for SYRE

Competitive view

SYRE vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Spyre Therapeutics, Inc. latest YouTube video thumbnail

Spyre Therapeutics, Inc.

SYRE

YouTube Spotify Podbean

Latest video

Q2 2026

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

SYRE

$9.09B

Spyre Therapeutics, Inc.

ISRG

$142.77B

Intuitive Surgical

JNJ

$629.14B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

SYRE

—

Spyre Therapeutics, Inc.

ISRG

45.8x

Intuitive Surgical

JNJ

30.3x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

SYRE

-29.9x

Spyre Therapeutics, Inc.

ISRG

33.0x

Intuitive Surgical

JNJ

21.2x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

SYRE

—

Spyre Therapeutics, Inc.

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

SYRE

—

Spyre Therapeutics, Inc.

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

SYRE

0.0%

Spyre Therapeutics, Inc.

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

SYRE

0.0%

Spyre Therapeutics, Inc.

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

SYRE

0.0%

Spyre Therapeutics, Inc.

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

SYRE

-23.0%

Spyre Therapeutics, Inc.

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

SYRE

-1.0%

Spyre Therapeutics, Inc.

ISRG

1.8%

Intuitive Surgical

JNJ

2.7%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

SYRE

—

Spyre Therapeutics, Inc.

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

SYRE

18.53x

Spyre Therapeutics, Inc.

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

SYRE

3.03

Spyre Therapeutics, Inc.

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

SYRE

—

Spyre Therapeutics, Inc.

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

SYRE

20.9%

Spyre Therapeutics, Inc.

ISRG

20.0%

Intuitive Surgical

JNJ

4.4%

Johnson & Johnson

Related research

Non-quarter videos featuring SYRE

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-10

SYRE Stock: Spyre Therapeutics Q2 2026 Earnings - The Beat Was Not Theirs #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for SYRE

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-10

Published youtube podcast complete

Spyre Therapeutics (SYRE) Q2 2026 Earnings: The 40-Cent Beat That Belongs To Somebody Else

Quarterly earnings-analysis entry for Spyre Therapeutics, Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music